Published in Ann Intern Med on January 01, 1995
Can unequal be more fair? Ethics, subject allocation, and randomised clinical trials. J Med Ethics (1998) 2.22
Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother (2000) 1.12
Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob Agents Chemother (1996) 1.03
Zalcitabine population pharmacokinetics: application of radioimmunoassay. Antimicrob Agents Chemother (1998) 0.78
Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystis carinii Pneumonia (PCP) before AIDS diagnosis in Italy. Eur J Epidemiol (1998) 0.78
AIDS Clinical Trials Group study numbers. Ann Intern Med (1995) 0.75
Combination antiretroviral therapy. Back to the future. Drugs (1995) 0.75
Early versus delayed treatment of HIV infection. Zidovudine should be given before symptoms develop. Drugs (1995) 0.75
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32
An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med (1992) 8.67
Factors related to errors in medication prescribing. JAMA (1997) 7.72
Ecology. Synthesizing U.S. river restoration efforts. Science (2005) 7.26
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med (1985) 6.54
Clinical and epidemiologic features of primary HIV infection. Ann Intern Med (1996) 6.04
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med (1992) 5.84
Plasma viremia in human immunodeficiency virus infection. N Engl J Med (1989) 5.73
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet (1991) 5.42
Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother (1993) 4.96
Evolution of organic aerosols in the atmosphere. Science (2009) 4.82
Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med (2001) 4.26
Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA (2001) 3.73
Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann Intern Med (1988) 3.71
Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann Intern Med (1992) 3.59
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother (1990) 3.26
Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis (1998) 2.98
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA (2000) 2.91
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med (1995) 2.66
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med (1990) 2.50
Prevention of Pneumocystis carinii pneumonitis in AIDS patients with weekly dapsone. Lancet (1990) 2.44
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 2.43
Differential binding of the insecticidal lectin GNA to human blood cells. Lancet (1999) 2.39
Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun (2010) 2.38
Neurologic relapse after benzathine penicillin therapy for secondary syphilis in a patient with HIV infection. N Engl J Med (1987) 2.32
Pulmonary cryptococcosis in patients without HIV infection. Chest (1999) 2.31
Why don't patients and physicians talk about end-of-life care? Barriers to communication for patients with acquired immunodeficiency syndrome and their primary care clinicians. Arch Intern Med (2000) 2.09
Sex differences in nevirapine rash. Clin Infect Dis (2000) 2.09
Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med (1993) 1.99
Agreement of umbilical cord drug and cotinine levels with maternal self-report of drug use and smoking during pregnancy. J Perinatol (2010) 1.98
Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta. J Cell Biol (1989) 1.97
A monoclonal antibody to the heavy chain of clathrin. EMBO J (1983) 1.94
Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. J Infect Dis (1998) 1.89
Seroepidemiology of human T-lymphotropic virus type III among homosexual men with the acquired immunodeficiency syndrome or generalized lymphadenopathy and among asymptomatic controls in Boston. Ann Intern Med (1985) 1.89
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med (1995) 1.89
Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med (1998) 1.88
Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis (1998) 1.88
Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. AIDS (1990) 1.85
Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol (1994) 1.85
Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology (2003) 1.83
The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study. Ann Intern Med (1990) 1.82
Chemical and microphysical characterization of ambient aerosols with the aerodyne aerosol mass spectrometer. Mass Spectrom Rev (2007) 1.80
Amphotericin B: delivery systems. Antimicrob Agents Chemother (1990) 1.78
Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS. Clin Infect Dis (1993) 1.77
Reversible oxidant-induced increases in albumin transfer across cultured endothelium: alterations in cell shape and calcium homeostasis. Blood (1985) 1.71
The attitudes of patients with advanced AIDS toward use of the medical futility rationale in decisions to forego mechanical ventilation. Arch Intern Med (2000) 1.69
Short-term reproducibility of a commercial interferon gamma release assay. Clin Vaccine Immunol (2009) 1.67
Characterization of serum neutralization response to the human immunodeficiency virus (HIV). AIDS Res Hum Retroviruses (1987) 1.65
Effects of zidovudine therapy in minority and other subpopulations with early HIV infection. JAMA (1991) 1.62
Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother (2001) 1.61
Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr (1999) 1.61
Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol (1993) 1.61
Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis (1998) 1.60
Some aspects of immunity in patients with cystic fibrosis. Clin Exp Immunol (1974) 1.60
Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin Neuropsychol (2012) 1.60
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS (2001) 1.59
Weight loss methods used by African American and Euro-American women. Res Nurs Health (1997) 1.59
Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis (2001) 1.58
Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci U S A (1993) 1.58
Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiviral chemotherapy. J Infect Dis (1991) 1.57
Olfactory dysfunction in LRRK2 G2019S mutation carriers. Neurology (2011) 1.57
Bladder cancer: approaches to prevention and control. Bull World Health Organ (1987) 1.56
Use of pulsed-field gel electrophoresis and flagellin gene typing in identifying clonal groups of Campylobacter jejuni and Campylobacter coli in farm and clinical environments. Appl Environ Microbiol (2001) 1.56
Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis (1994) 1.55
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.55
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med (2008) 1.54
Diagnosing symptomatic HIV-associated neurocognitive disorders: self-report versus performance-based assessment of everyday functioning. J Int Neuropsychol Soc (2011) 1.53
Dispersal as a regional process affecting the local dynamics of marine and stream benthic invertebrates. Trends Ecol Evol (1996) 1.50
Bacteremia in hospitalized patients infected with the human immunodeficiency virus: a case-control study of risk factors and outcome. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.47
Nutritional supplementation in treatment of cystic fibrosis of the pancreas. Am J Dis Child (1973) 1.44
Aerosol pentamidine prophylaxis following Pneumocystis carinii pneumonia in AIDS patients: results of a blinded dose-comparison study using an ultrasonic nebulizer. Am J Med (1991) 1.41
Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (2000) 1.41
The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA (1994) 1.41
The quality of patient-doctor communication about end-of-life care: a study of patients with advanced AIDS and their primary care clinicians. AIDS (1999) 1.41
Effect of proteoglycan removal on solute mobility in articular cartilage. J Biomech (1997) 1.41
The gene for human complement C9 is on chromosome 5. Genomics (1989) 1.40
Building integrated systems--driving the nitroglycerin truck. Healthc Forum J (1993) 1.40
Widespread dissemination of Pneumocystis carinii infection in a patient with acquired immune deficiency syndrome receiving long-term treatment with aerosolized pentamidine. Am J Clin Pathol (1991) 1.39
Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol Lett (1994) 1.38
Lingual hemorrhage in a patient with hemophilia A complicated by a high titer inhibitor. Management by continuous infusion of monoclonal antibody-purified factor VIII. Am J Pediatr Hematol Oncol (1993) 1.38
Prophylaxis and treatment of opportunistic infection in patients on HAART. AIDS Read (2003) 1.38
A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics (1995) 1.37
Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother (1995) 1.36
Immune complexes in cystic fibrosis. Br Med J (1975) 1.36